Adalimumab

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Generalized Pustular Psoriasis (GPP)

Conditions

Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese

Trial Timeline

Sep 28, 2015 → Jul 20, 2017

NCT ID

NCT02533375

About Adalimumab

Adalimumab is a phase 3 stage product being developed by AbbVie for Generalized Pustular Psoriasis (GPP). The current trial status is completed. This product is registered under clinical trial identifier NCT02533375. Target conditions include Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05414201	Approved	Completed	Jul 7, 2022	Jun 10, 2024	Non-infectious Intermediate Posterior- or Pan-uveitis
NCT04183608	Approved	Recruiting	Jan 14, 2020	May 1, 2028	Ulcerative Colitis
NCT03311464	Phase 3	Completed	Oct 27, 2017	Apr 21, 2020	Pyoderma Gangrenosum
NCT03261102	Pre-clinical	Active	Jan 17, 2017	Jun 1, 2025	Crohn Disease
NCT02897115	Approved	Terminated	Sep 12, 2016	Dec 21, 2017	Axial Spondyloarthritis
NCT02904902	Phase 3	Completed	Sep 6, 2016	May 30, 2019	Hidradenitis Suppurativa
NCT02668640	Pre-clinical	Completed	May 1, 2016	Aug 13, 2018	Rheumatoid Arthritis
NCT02750800	Pre-clinical	Completed	Apr 7, 2016	Apr 3, 2018	Rheumatoid Arthritis
NCT02739828	Pre-clinical	Completed	Apr 7, 2016	Mar 28, 2018	Hidradenitis Suppurativa
NCT02634541	Approved	UNKNOWN	Jan 1, 2016	Dec 1, 2017	Ankylosing Spondyloarthritis
NCT02632175	Phase 3	Completed	Nov 26, 2015	Apr 8, 2025	Ulcerative Colitis
NCT02533375	Phase 3	Completed	Sep 28, 2015	Jul 20, 2017	Generalized Pustular Psoriasis (GPP)
NCT02499783	Phase 3	Completed	Aug 17, 2015	Dec 15, 2017	Crohn's Disease
NCT02198651	Approved	Completed	Jan 5, 2015	Aug 8, 2018	Rheumatoid Arthritis
NCT02333383	Pre-clinical	Completed	Dec 31, 2014	Aug 8, 2017	Ankylosing Spondylitis
NCT02539849	Pre-clinical	Completed	Dec 1, 2014	Dec 19, 2017	Crohn Disease
NCT02185014	Phase 3	Completed	Aug 12, 2014	Nov 3, 2017	Crohn's Disease
NCT02148718	Approved	Completed	Jun 1, 2014	Jan 1, 2017	Moderate to Severe Crohn's Disease
NCT02065622	Phase 3	Completed	Mar 27, 2014	Nov 11, 2019	Ulcerative Colitis (UC)
NCT02016482	Phase 3	Completed	Jan 1, 2014	Apr 1, 2016	Nail Psoriasis

Competing Products

20 competing products in Generalized Pustular Psoriasis (GPP)

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	65
Satralizumab	Chugai Pharmaceutical	Phase 3	77
Perampanel	Eisai	Pre-clinical	23
Perampanel + Placebo comparator	Eisai	Phase 3	77
zonisamide	Eisai	Pre-clinical	23
Fycompa	Eisai	Pre-clinical	23
Fycompa	Eisai	Pre-clinical	23
Perampanel	Eisai	Phase 3	77
Perampanel	Eisai	Pre-clinical	23
Cenobamate	Ono Pharmaceutical	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Approved	85
Ixekizumab	Eli Lilly	Approved	85
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	52
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	85
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	52
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	52
ABBV-932 + Placebo	AbbVie	Phase 1	33
Escitalopram	AbbVie	Approved	85
Quetiapine fumarate + Paroxetine	AstraZeneca	Phase 3	77

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved

CREONApproved

Venetoclax + AzacitidineApproved

Oxybutynin + PlaceboApproved

Glecaprevir-pibrentasvirApproved